Teva rethink

摘要

Israeli pharmaceutical firm Teva, the world's largest maker of generic drugs, may shift its focus towards branded medicines after it announced a new chief executive. Jeremy Levin, former head of strategy and alliances at Bristol-Myers Squibb in New York City, has a reputation for making external partnerships and acquisitions and is expected to continue his approach at Teva, which is headquartered near Tel Aviv. "Medicines are medicines," he told investors in a conference call on 3 January. "It doesn't matter if they are branded or generic."